Ignite Creation Date:
2025-12-25 @ 12:37 AM
Ignite Modification Date:
2025-12-27 @ 4:58 AM
Study NCT ID:
NCT00012467
Status:
COMPLETED
Last Update Posted:
2009-06-03
First Post:
2001-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
Sponsor:
InterMune
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
B013
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Steven Porter, MD, PhD
Old Organization:
InterMune Pharmaceuticals Inc.